The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - AstraZeneca; Bayer; Lilly; MSD; Roche
18F-FDG PET–derived parameter total lesion glycolisis (TLG) as a tool to stratify patients (pts) with advanced non–small cell lung cancer (aNSCLC) treated with immunotherapy.
 
Filippo Gustavo Dall'Olio
No Relationships to Disclose
 
Camilo Garcia
No Relationships to Disclose
 
Valentina Ambrosini
No Relationships to Disclose
 
Marco Tagliamento
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche; Takeda
Other Relationship - Amgen; Novartis
 
Carole Helissey
No Relationships to Disclose
 
Monica Velasco
No Relationships to Disclose
 
Mohamed Aymen Bettayeb
No Relationships to Disclose
 
Mihaela Aldea
No Relationships to Disclose
 
Nicole Conci
No Relationships to Disclose
 
Matteo Bauckneht
No Relationships to Disclose
 
Gerald Bonardel
No Relationships to Disclose
 
Giulia Argalia
No Relationships to Disclose
 
Davide Soldato
No Relationships to Disclose
 
Eugenia Cella
No Relationships to Disclose
 
Jordi Remon Masip
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; OSE Immunotherapeutics; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Inivata; OSE Immunotherapeutics; OSE Immunotherapeutics; Roche/Genentech
 
David Planchard
Honoraria - PeerVoice; Prime Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/Astra Zeneca; Janssen; MedImmune; MSD Oncology; Novartis; Pfizer; Roche; Samsung
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst)
 
Corinne Balleyguier
No Relationships to Disclose
 
Andrea Ardizzoni
No Relationships to Disclose
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Seagen; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
 
Benjamin Besse
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); cergentis (Inst); Chugai Pharma (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Turning Point Therapeutics (Inst)